pharmaphorum

FEBRUARY 3, 2021

While achieving the Nobel Prize spotlight would have been enough to impress, CRISPR-Cas9 gene editing is part of a growing list of technologies granted Investigational New Drug (IND) applications with early data from clinical trials supporting its safe use in edited cells re-introduced into a patient.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

XTalks

JANUARY 21, 2025

In a clinical trial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. In a trial with 100 patients , the device demonstrated no major complications, an average bleeding stop time of 2 minutes, with patients walking within approximately 2.5

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

OCTOBER 14, 2020

A paper on the clinical trial results published in JAMA Oncology demonstrates the effectiveness of Savran Tech’s CTC detection technology with real world patients. The trial involved about 200 patients with early stage triple negative breast cancer who received chemotherapy and underwent surgery. “We About This Clinical Trial.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genomics 40

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

XTalks

JANUARY 6, 2025

For example, antisense oligonucleotide (ASO)-based therapies have gained traction, with 100 Phase I clinical trials initiated and around 25 percent of these advancing to Phase II or Phase III trials in recent years. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future. billion by 2031.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111